Linked Life Data

15205362

Source:http://linkedlifedata.com/resource/pubmed/id/15205362

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
11
pubmed:dateCreated
2004-11-2
pubmed:abstractText
Somatostatin receptor subtypes, especially subtype 2 (SSTR2), exert their antitumor (cytostatic and/or cytotoxic) and anti-angiogenic effects. Here we aimed to investigate the anti-angiogenic effect of SSTR2 gene transfer into pancreatic cancer cell line PC-3, and the mechanisms involved in this effect. The full-length human SSTR2 complementary DNA was introduced into pancreatic cancer cell line PC-3 by lipofectamine-mediated transfection, and stable expression of SSTR2 was detected by immunohistochemistry and RT-PCR. Athymic mice were separately xenografted with SSTR2-expressing cells (experimental group), vector control and mock control cells. Intratumoral microvessel density (MVD) was assessed by immunohistochemistry. Immunohistochemistry and RT-PCR were used to determine the expression of angiogenic factors vascular endothelial growth factor (VEGF), basic fibroblast growth factor (bFGF) and matrix metalloproteinase (MMP)-2 in xenograft tumors. MVD was significantly lower in the experimental group (5.16 +/- 1.34) than that in the vector control (16.52 +/- 2.25) and mock control (15.32 +/- 2.53) (P < 0.05). The immunohistochemical assay showed a significant decrease in the expression of VEGF, bFGF and MMP-2 protein in the experimental group compared with the vector control and mock control, considering both the integral optical density and area of staining (P < 0.05). RT-PCR showed a significant reduction of VEGF, bFGF and MMP-2 mRNA expression in the experimental group compared with the vector control and mock control (P < 0.05). Thus, introduction of the SSTR2 gene, the expression of which is frequently lost in human pancreatic adenocarcinoma, exerts its anti-angiogenic effects by down-regulating the expression of the factors, which are involved in tumor angiogenesis and metastasis, suggesting SSTR2 gene transfer as a promising strategy of gene therapy for pancreatic cancer.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Nov
pubmed:issn
0143-3334
pubmed:author
pubmed:issnType
Print
pubmed:volume
25
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
2075-81
pubmed:meshHeading
pubmed-meshheading:15205362-Angiogenesis Inhibitors, pubmed-meshheading:15205362-Animals, pubmed-meshheading:15205362-Cell Line, Tumor, pubmed-meshheading:15205362-DNA, Complementary, pubmed-meshheading:15205362-Fibroblast Growth Factor 2, pubmed-meshheading:15205362-Humans, pubmed-meshheading:15205362-Matrix Metalloproteinase 2, pubmed-meshheading:15205362-Mice, pubmed-meshheading:15205362-Mice, Nude, pubmed-meshheading:15205362-Neoplasm Transplantation, pubmed-meshheading:15205362-Pancreatic Neoplasms, pubmed-meshheading:15205362-RNA, Messenger, pubmed-meshheading:15205362-Receptors, Somatostatin, pubmed-meshheading:15205362-Reverse Transcriptase Polymerase Chain Reaction, pubmed-meshheading:15205362-Transplantation, Heterologous, pubmed-meshheading:15205362-Vascular Endothelial Growth Factor A
pubmed:year
2004
pubmed:articleTitle
Anti-angiogenic effects of somatostatin receptor subtype 2 on human pancreatic cancer xenografts.
pubmed:affiliation
Department of Surgery, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430030, Hubei Province, China.
pubmed:publicationType
Journal Article, Research Support, Non-U.S. Gov't